5 articles tagged with #r-and-d. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
Stanford researchers have developed AI scientist agents that dramatically accelerate drug discovery, reducing timelines from months to days. This breakthrough could significantly speed up treatment development during health emergencies and reshape pharmaceutical R&D processes.
Amgen CEO Bob Bradway made early bets on AI in biotech, positioning the company to leverage artificial intelligence for drug discovery and development. The strategy is now generating measurable returns while forcing the organization to navigate tensions between AI-driven automation and the need for specialized scientific expertise.
Researchers propose new metrics to measure the automation of AI R&D (AIRDA), arguing that existing capability benchmarks don't capture real-world automation effects or broader consequences. The proposed metrics would track dimensions like capital allocation, researcher time, and AI oversight incidents to help decision-makers understand AIRDA's impact on AI progress and safety.
Researchers developed an advanced AI classifier achieving 97% precision in identifying AI patents, revealing that both the U.S. and China are rapidly expanding AI innovation but through fundamentally different institutional structures. While China recently surpassed the U.S. in annual patent volume, American AI patenting remains concentrated among large private firms, whereas Chinese innovation is more geographically dispersed across universities and state-owned enterprises.
The Ethereum Foundation has opened applications for its 2026 Internship Program, offering paid full-time positions for students to work directly with EF teams. The 12-week summer program will involve contributing to active R&D and ecosystem-oriented projects across various aspects of Ethereum protocol development.
